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To the Editor,
Allergen immunotherapy (AIT) is effective in allergic rhinitis (AR) and/or asthma. 
Randomized controlled trials (RCTs) have demonstrated efficacy and safety of both 
subcutaneous (SCIT) and sublingual (SLIT) in patients allergic to pollen and house dust mites. 
1 RCTs are mandatory for market authorization of AIT products but they lack real-world data 
(RWD). Many AIT guidelines have been formulated but they have not imputed RWD. 
Observational studies with RWD complement RCTs and provide novel information on AIT in 
real life. The European Academy of Allergy and Clinical Immunology (EAACI) emphasized 
the value of RWD data in AIT 2.
This proof-of-concept (POC) study aimed to assess the effects of AIT in AR using RWD 
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All MASK-air® data from May 21, 2015 to December 6, 2020, in 25 countries have been 
analysed. MASK-air® comprises a daily questionnaire in which users are asked to answer six 
questions assessing AR symptoms visual analogue scales (VASs), and provide information on 
AIT and medication. 
Days of participants using AIT use were compared to days from non-AIT participants using (i) 
daily global symptoms VAS (how much allergy symptoms were bothering the user), and ii) 
work VAS (impact of allergic symptoms on work). Separate analyses were performed for (i) 
days when no medication, (ii) days with monotherapy (single drug formulation), and (iii) days 
with co-medication (more than one drug formulation) were used. Sensitivity analyses were 
performed with the AIT group comprising data from users under AIT irrespective of the days 
when AIT was effectively done. 
Continuous variables are presented as medians (with 95% confidence intervals [CI]) and 
interquartile ranges (IQR). Median VAS values were compared using the Mann-Whitney U 
test. 
Results 
317,176 days of MASK-air® (17,870 users) were analysed, of which 138,304 (43.6%) involved 
the reporting of medication(s) and 36,229 (11.4%) of AIT.
We observed a global symptoms median VAS of 9 (95%CI=[9-9]) for days of users treated by 
AIT versus 12 (95%CI=[12-12], p<0.001) for days of non-AIT users (Table 1). The median 
global symptoms VASs were lower even when considering (i) days under no medication (7 
versus 8), (ii) days under monotherapy (11 versus 14), or (iii) days under co-medication (17 
versus 20).
Similar results were found i) for Work VAS (Table 1) and ii) for data of users reporting the use 
of  AIT (Supplementary Table 1).
Table 1: Impact of AIT on real world data using MASK-air®




AIT No AIT AIT No AIT
P value
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9 [9-9] (24) 12 [12-12] (28) <0.001




7 [6-7] (19) 8 [8-8] (24) <0.001
Single 
medication
8712 (10.4) 75,291 (89.6) 11 [11-12] 
(24)
14 [14-15] (28) <0.001
Comedication 5904 (10.9) 48,397 (88.1) 17 [16-18] 
(31)
20 [19-20] (35) <0.001




AIT No AIT AIT No AIT




6 [6-6] (18) 8 [8-8] (23) <0.001
No medication 10,465 
(12.5)
73,024 (87.5) 4 [4-4] (15) 5 [5-6] (18) <0.001
Single 
medication
4472 (11.0) 35,997 (89.0) 8 [7-8] (18) 10 [10-10] (23) <0.001
Comedication 2793 (10.8) 22,981 (88.2) 12 [11-13] 
(27)
15 [14-15] (30) <0.001
CI=Confidence interval; IQR=Interquartile range; Symptoms VAS = MASK-air® visual analogue scale assessing the 
severity of overall allergic symptoms on that day; Work VAS = MASK-air® visual analogue scale assessing the 
work impact of allergic symptoms on that day
Conclusions and limitations
This POC indicates that MASK-air® is a valuable tool for assessing AIT. The results of this study 
accord with previous studies in 3,000 and 9,900 patients.5 The overall effect on VAS global 
symptoms or work is around 25%. Interestingly, the same magnitude of effect is observed for 
days without treatment, monotherapy and co-medication.   
Median levels of VAS are low, and this can be explained by variable exposure to allergens, 
patients continuing their treatment without allergen exposure, and effective treatment (Table 
2, from data previously published 6).
Table 2: Differences in VAS global symptoms during and outside of the expected pollen 
season in the European dataset of MASK 6
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During pollen season
N observations/days (N 
users)
3286 (331) 2594 (159) 4093 (351) 9780 (1414) 23377 (3736)
VAS day 1 – median [p25-
p75]
50 [28-71] 52 [25-73] 50 [30-75] 55 [30-75] 40 [15-56]
VAS all days – median [p25-
p75]
26 [8-50] 16 [6-38] 19 [7-39] 14 [3-38] 14 [3-38]
Outside pollen season
N observations/days (N 
users)
1116 (99) 1258 (80) 1437 (95) 1956 (275) 13,120 (1299)
VAS day 1 – median [p25-
p75]
44 [19-67] 34.5 [15-62] 46 [17-64] 38 [18-66] 29 [6-50]
VAS all days – median [p25-
p75]
19 [5-44] 18 [7-36] 14 [5-34] 19 [5-47] 5 [0-20]
These results show: (i) symptoms on day 1 are more severe than during the course of the study. This suggests that 
treatment is effective and/or that exposure to allergen varies; (ii) symptoms on day 1 are more severe during the 
pollen season than outside; and (iii) median symptoms on day 1 during the pollen season are moderate for OAH 
mono and moderate-severe for INCS. FF=Fluticasone Furoate; MF=Mometasone Furoate; MPAzeFlu=Azelastine-
Fluticasone-Propionate; OAH=Oral antihistamines; VAS=Visual analogue scale (assessing the severity of overall 
allergic symptoms on that day); p25-p75=percentile 25-percentile 75.
Patients used the app for an average of 17.5 days. Since data of the allergen exposure 
(particularly on the daily amounts of pollen for each region) are not available yet, it was not 
possible to refer to patients’ personalized pollen exposure or to exclude days without allergen 
exposure from this analysis. Another limitation concerns the possibility of differences in care 
and adherence between users who regularly receive AIT or not. However, this study was not 
designed to compare the magnitude of efficacy of different AIT products, to differentiate 
between administration routes or treatment schedules of AIT, or between allergens. It 
attempted to confirm the value of MASK-air® in AIT. Based on this POC-trial, subsequent 
analyses will investigate effect sizes of different routes of administration, allergen-groups, 
impact of natural allergen exposure, and country specific differences. 1 
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